Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06213259Phase 1Completed

A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)

Role: lead

NCT05906524Phase 1Unknown

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Role: lead

NCT05723432Phase 1Unknown

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Role: lead

NCT05230290Phase 1Completed

Clinical Study of KD6001 in Advanced Solid Tumours

Role: lead

All 4 trials loaded